|
1
|
Nikolaos P, Vasilios L, Efstratios K,
Panagiotis A, Christos P, Nikolaos B, Antonios H, Tsakiridis K,
Zarogoulidis P, Zarogoulidis K, et al: Therapeutic modalities for
Pancoast tumors. J Thorac Dis. 6 (Suppl 1):S180–S193.
2014.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Detterbeck FC: Changes in the treatment of
Pancoast tumors. Ann Thorac Surg. 75:1990–1997. 2003.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Marulli G, Battistella L, Mammana M,
Calabrese F and Rea F: Superior sulcus tumors (Pancoast tumors).
Ann Transl Med. 4(239)2016.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Chardack WM and Maccallum JD: Pancoast
tumor; five-year survival without recurrence or metastases
following radical resection and postoperative irradiation. J Thorac
Surg. 31:535–542. 1956.PubMed/NCBI
|
|
5
|
Shaw RR, Paulson DL and Kee JL: Treatment
of superior sulcus tumor by irradiation followed by resection. Ann
Surg. 154:29–40. 1961.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Shaw RR: Pancoast's tumor. Ann Thorac
Surg. 37:343–345. 1984.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Martínez-Monge R, Herreros J, Aristu JJ,
Aramendía JM and Azinovic I: Combined treatment in superior sulcus
tumors. Am J Clin Oncol. 17:317–322. 1994.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Attar S, Krasna MJ, Sonett JR, Hankins JR,
Slawson RG, Suter CM and McLaughlin JS: Superior sulcus (Pancoast)
tumor: Experience with 105 patients. Ann Thorac Surg. 66:193–198.
1998.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Barnes JB, Johnson SB, Dahiya RS, Temes
RT, Herman TS and Thomas CR Jr: Concomitant weekly cisplatin and
thoracic radiotherapy for Pancoast tumors of the lung: Pilot
experience of the San Antonio cancer institute. Am J Clin Oncol.
25:90–92. 2002.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Rusch VW, Giroux DJ, Kraut MJ, Crowley J,
Hazuka M, Winton T, Johnson DH, Shulman L, Shepherd F, Deschamps C,
et al: Induction chemoradiation and surgical resection for superior
sulcus non-small-cell lung carcinomas: Long-term results of
Southwest oncology group trial 9416 (Intergroup Trial 0160). J Clin
Oncol. 25:313–318. 2007.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Pourel N, Santelmo N, Naafa N, Serre A,
Hilgers W, Mineur L, Molinari N and Reboul F: Concurrent
cisplatin/etoposide plus 3D-conformal radiotherapy followed by
surgery for stage IIB (superior sulcus T3N0)/III non-small cell
lung cancer yields a high rate of pathological complete response.
Eur J Cardiothorac Surg. 33:829–836. 2008.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Kunitoh H, Kato H, Tsuboi M, Shibata T,
Asamura H, Ichinose Y, Katakami N, Nagai K, Mitsudomi T, Matsumura
A, et al: Phase II trial of preoperative chemoradiotherapy followed
by surgical resection in patients with superior sulcus
non-small-cell lung cancers: Report of Japan clinical oncology
group trial 9806. J Clin Oncol. 26:644–649. 2008.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Kappers I, Belderbos JS, Burgers JA, van
Zandwijk N, Groen HJ and Klomp HM: Non-small cell lung carcinoma of
the superior sulcus: Favourable outcomes of combined modality
treatment in carefully selected patients. Lung Cancer. 59:385–390.
2008.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Albain KS, Rusch VW, Crowley JJ, Rice TW,
Turrisi AT III, Weick JK, Lonchyna VA, Presant CA, McKenna RJ and
Gandara DR: Concurrent cisplatin/etoposide plus chest radiotherapy
followed by surgery for stages IIIA (N2) and IIIB non-small-cell
lung cancer: Mature results of Southwest oncology group phase II
study 8805. J Clin Oncol. 13:1880–1892. 1995.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Jensen MP and Karoly P: Self-report scales
and procedures for assessing pain in adults. In: Turk DC, Melzack R
(eds). Handbook of Pain Assessment, 2nd edn. Guilford Publications:
New York: pp 15-34, 2001.
|
|
16
|
Kang Y and Demiris G: Self-report pain
assessment tools for cognitively intact older adults: Integrative
review. Int J Older People Nurs. 13(e12170)2018.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Simmons SF, Schnelle JF, Saraf AA, Coelho
CC, Jacobsen JM, Kripalani S, Bell S, Mixon A and Vasilevskis EE:
Pain and satisfaction with pain management among older patients
during the transition from acute to skilled nursing care.
Gerontologist. 56:1138–1145. 2016.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Kondrup J, Rasmussen HH, Hamberg O and
Stanga Z: Ad Hoc ESPEN Working Group. Nutritional risk screening
(NRS 2002): A new method based on an analysis of controlled
clinical trials. Clin Nutr. 22:321–336. 2003.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Detterbeck FC, Boffa DJ, Kim AW and Tanoue
LT: The eighth edition lung cancer stage classification. Chest.
151:193–203. 2017.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Felip E and Rosell R: New strategies in
the treatment of resectable non-small cell lung cancer. Expert Rev
Anticancer Ther. 1:224–228. 2001.PubMed/NCBI View Article : Google Scholar
|
|
21
|
Waseda R, Klikovits T, Hoda MA,
Hoetzenecker K, Bertoglio P, Dieckmann K, Zöchbauer-Müller S,
Pirker R, Prosch H, Döme B and Klepetko W: Trimodality therapy for
Pancoast tumors: T4 is not a contraindication to radical surgery. J
Surg Oncol. 116:227–235. 2017.PubMed/NCBI View Article : Google Scholar
|
|
22
|
Roth JA, Fossella F, Komaki R, Ryan MB,
Putnam JB Jr, Lee JS, Dhingra H, De Caro L, Chasen M and McGavran
M: A randomized trial comparing perioperative chemotherapy and
surgery with surgery alone in resectable stage IIIA non-small-cell
lung cancer. J Natl Cancer Inst. 86:673–680. 1994.PubMed/NCBI View Article : Google Scholar
|
|
23
|
Rosell R, Gómez-Codina J, Camps C, Maestre
J, Padille J, Cantó A, Mate JL, Li S, Roig J and Olazábal A: A
randomized trial comparing preoperative chemotherapy plus surgery
with surgery alone in patients with non-small-cell lung cancer. N
Engl J Med. 330:153–158. 1994.PubMed/NCBI View Article : Google Scholar
|
|
24
|
Pisters KM, Vallières E, Crowley JJ,
Franklin WA, Bunn PA Jr, Ginsberg RJ, Putnam JB Jr, Chansky K and
Gandara D: Surgery with or without preoperative paclitaxel and
carboplatin in early-stage non-small-cell lung cancer: Southwest
oncology group trial S9900, an intergroup, randomized, phase III
trial. J Clin Oncol. 28:1843–1849. 2010.PubMed/NCBI View Article : Google Scholar
|
|
25
|
Zhong WZ, Chen KN, Chen C, Gu CD, Wang J,
Yang XN, Mao WM, Wang Q, Qiao GB, Cheng Y, et al: Erlotinib versus
gemcitabine plus cisplatin as neoadjuvant treatment of stage
IIIA-N2 EGFR-mutant non-small-cell lung cancer (EMERGING-CTONG
1103): A randomized phase II study. J Clin Oncol. 37:2235–2245.
2019.PubMed/NCBI View Article : Google Scholar
|
|
26
|
Hishida T, Nagai K, Mitsudomi T, Yokoi K,
Kondo H, Horinouchi H, Akiyama H, Nagayasu T and Tsuboi M: Japan
Clinical Oncology Group. Salvage surgery for advanced non-small
cell lung cancer after response to gefitinib. J Thorac Cardiovasc
Surg. 140:e69–e71. 2010.PubMed/NCBI View Article : Google Scholar
|
|
27
|
Lara-Guerra H, Chung CT, Schwock J,
Pintilie M, Hwang DM, Leighl NB, Waddell TK and Tsao MS:
Histopathological and immunohistochemical features associated with
clinical response to neoadjuvant gefitinib therapy in early stage
non-small cell lung cancer. Lung Cancer. 76:235–241.
2012.PubMed/NCBI View Article : Google Scholar
|
|
28
|
Schaake EE, Kappers I, Codrington HE,
Olmos RA, Teertstra HJ, van Pel R, Burgers JA, van Tinteren H and
Klomp HM: Tumor response and toxicity of neoadjuvant erlotinib in
patients with early-stage non-small-cell lung cancer. J Clin Oncol.
30:2731–2738. 2012.PubMed/NCBI View Article : Google Scholar
|
|
29
|
Zhong W, Yang X, Yan H, Zhang X, Su J,
Chen Z, Liao R, Nie Q, Dong S, Zhou Q, et al: Phase II study of
biomarker-guided neoadjuvant treatment strategy for IIIA-N2
non-small cell lung cancer based on epidermal growth factor
receptor mutation status. J Hematol Oncol. 8(54)2015.PubMed/NCBI View Article : Google Scholar
|
|
30
|
Sun L, Guo YJ, Song J, Wang YR, Zhang SL,
Huang LT, Zhao JZ, Jing W, Han CB and Ma JT: Neoadjuvant EGFR-TKI
therapy for EGFR-mutant NSCLC: A systematic review and pooled
analysis of five prospective clinical trials. Front Oncol.
10(586596)2020.PubMed/NCBI View Article : Google Scholar
|
|
31
|
Cansouline X, Lipan B, Sizaret D, Tallet
A, Vandier C, Carmier D and Legras A: EGFR-mutant non-small-cell
lung cancer at surgical stages: What is the place for tyrosine
kinase inhibitors? Cancers (Basel). 14(2257)2022.PubMed/NCBI View Article : Google Scholar
|
|
32
|
Xiong L, Lou Y, Bai H, Li R, Xia J, Fang
W, Zhang J, Han-Zhang H, Lizaso A, Li B, et al: Efficacy of
erlotinib as neoadjuvant regimen in EGFR-mutant locally advanced
non-small cell lung cancer patients. J Int Med Res.
48(300060519887275)2020.PubMed/NCBI View Article : Google Scholar
|
|
33
|
Zhang Y, Fu F, Hu H, Wang S, Li Y, Hu H
and Chen H: Gefitinib as neoadjuvant therapy for resectable stage
II-IIIA non-small cell lung cancer: A phase II study. J Thorac
Cardiovasc Surg. 161:434–442.e2. 2021.PubMed/NCBI View Article : Google Scholar
|
|
34
|
Chen WQ, Li P, Wang Q, Zhang YJ, Li HY,
Jin XT, Yan S, Kou GF, Cai SL and Liu G: A randomized controlled
study of erlotinib versus pemetrexed combined with cisplatin in
neoadjuvant therapy of stage A EGFR-mutant lung adenocarcinoma.
Zhonghua Zhong Liu Za Zhi. 40:133–137. 2018.PubMed/NCBI View Article : Google Scholar : (In Chinese).
|
|
35
|
Liu M, Jiang G, He W, Zhang P and Song N:
Surgical resection of locally advanced pulmonary adenocarcinoma
after gefitinib therapy. Ann Thorac Surg. 92:e11–e12.
2011.PubMed/NCBI View Article : Google Scholar
|
|
36
|
Feng S, Qiang Z, Wanwan C, Zhaozhun Z,
Yuewu X and Shencun F: Case report: Aumolertinib as neoadjuvant
therapy for patients with unresectable Stage III non-small cell
lung cancer with activated EGFR mutation: Case series. Front Oncol.
12(872225)2022.PubMed/NCBI View Article : Google Scholar
|
|
37
|
Arcasoy SM and Jett JR: Superior pulmonary
sulcus tumors and Pancoast's syndrome. N Engl J Med. 337:1370–1376.
1997.PubMed/NCBI View Article : Google Scholar
|
|
38
|
Tang WF, Xu W, Huang WZ, Lin GN, Zeng YM,
Lin JS, Wu M, Bao H, Peng JW, Jiang HM, et al: Pathologic complete
response after neoadjuvant tislelizumab and chemotherapy for
Pancoast tumor: A case report. Thorac Cancer. 12:1256–1259.
2021.PubMed/NCBI View Article : Google Scholar
|
|
39
|
Zhong WZ, Wang Q, Mao WM, Xu ST, Wu L, Wei
YC, Liu YY, Chen C, Cheng Y, Yin R, et al: Gefitinib versus
vinorelbine plus cisplatin as adjuvant treatment for stage II-IIIA
(N1-N2) EGFR-mutant NSCLC: Final overall survival analysis of
CTONG1104 phase III trial. J Clin Oncol. 39:713–722.
2021.PubMed/NCBI View Article : Google Scholar
|
|
40
|
Rice JD, Heidel J, Trivedi JR and van
Berkel VH: Optimal surgical timing after neoadjuvant therapy for
Stage IIIa non-small cell lung cancer. Ann Thorac Surg.
109:842–847. 2020.PubMed/NCBI View Article : Google Scholar
|
